Search Results

Shineco Inc. announced that on June 18, 2024, it entered into an Investment Letter of Intent with Beijing Oriental Meitong Technology Co., Ltd. whereby Shineco intends to invest $20 million in Meitong Technology in exchange for 80% of Meitong Technology’s shares.

Shineco, Inc., a provider of innovative diagnostic medical products and related medical devices, announced that on June 20, 2024, the Company entered into a Securities Purchase Agreement with certain non-U.S. investors.

Shineco Inc. announced today that on June 5, 2024, the Company received a formal notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

Shineco Inc. announced that on June 14, 2024, its 51% owned subsidiary, Shangkang Life Science and Technology Co., Ltd. entered into a Strategic Cooperation Framework Agreement with Turing Video Co., Ltd to jointly develop a series of smart medical products and introduce their biotechnology and other innovative health solutions to the healthcare market.

Shineco, Inc. announced that the Company’s Board of Directors has approved a reverse stock split of its issued and outstanding shares of common stock, par value $0.001 per share, at a ratio of 1-for-10.

Shineco, Inc. announced that it plans to increase its research and development of new high-tech applications of silk protein in the health and medical field in conjunction with its existing silkworm business segment.